Literature DB >> 18060041

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

Carolina Berger1, Michael C Jensen, Peter M Lansdorp, Mike Gough, Carole Elliott, Stanley R Riddell.   

Abstract

The adoptive transfer of antigen-specific T cells that have been expanded ex vivo is being actively pursued to treat infections and malignancy in humans. The T cell populations that are available for adoptive immunotherapy include both effector memory and central memory cells, and these differ in phenotype, function, and homing. The efficacy of adoptive immunotherapy requires that transferred T cells persist in vivo, but identifying T cells that can reproducibly survive in vivo after they have been numerically expanded by in vitro culture has proven difficult. Here we show that in macaques, antigen-specific CD8(+) T cell clones derived from central memory T cells, but not effector memory T cells, persisted long-term in vivo, reacquired phenotypic and functional properties of memory T cells, and occupied memory T cell niches. These results demonstrate that clonally derived CD8+ T cells isolated from central memory T cells are distinct from those derived from effector memory T cells and retain an intrinsic capacity that enables them to survive after adoptive transfer and revert to the memory cell pool. These results could have significant implications for the selection of T cells to expand or to engineer for adoptive immunotherapy of human infections or malignancy.

Entities:  

Mesh:

Year:  2008        PMID: 18060041      PMCID: PMC2104476          DOI: 10.1172/JCI32103

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  51 in total

Review 1.  Arrested differentiation, the self-renewing memory lymphocyte, and vaccination.

Authors:  D T Fearon; P Manders; S D Wagner
Journal:  Science       Date:  2001-07-13       Impact factor: 47.728

2.  The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells.

Authors:  Noriko Sato; Hiral J Patel; Thomas A Waldmann; Yutaka Tagaya
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-03       Impact factor: 11.205

3.  Development and homeostasis of T cell memory in rhesus macaque.

Authors:  Christine J Pitcher; Shoko I Hagen; Joshua M Walker; Richard Lum; Bridget L Mitchell; Vernon C Maino; Michael K Axthelm; Louis J Picker
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

4.  Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells.

Authors:  Kimberly S Schluns; Kristina Williams; Averil Ma; Xin X Zheng; Leo Lefrançois
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

5.  Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma.

Authors:  M E Dudley; J Wunderlich; M I Nishimura; D Yu; J C Yang; S L Topalian; D J Schwartzentruber; P Hwu; F M Marincola; R Sherry; S F Leitman; S A Rosenberg
Journal:  J Immunother       Date:  2001 Jul-Aug       Impact factor: 4.456

6.  Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.

Authors:  T Stanislawski; R H Voss; C Lotz; E Sadovnikova; R A Willemsen; J Kuball; T Ruppert; R L Bolhuis; C J Melief; C Huber; H J Stauss; M Theobald
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

7.  Immunotherapy through TCR gene transfer.

Authors:  H W Kessels; M C Wolkers; M D van den Boom; M A van der Valk; T N Schumacher
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

8.  IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice.

Authors:  J Marks-Konczalik; S Dubois; J M Losi; H Sabzevari; N Yamada; L Feigenbaum; T A Waldmann; Y Tagaya
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

9.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Authors:  Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

10.  Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells.

Authors:  Todd C Becker; E John Wherry; David Boone; Kaja Murali-Krishna; Rustom Antia; Averil Ma; Rafi Ahmed
Journal:  J Exp Med       Date:  2002-06-17       Impact factor: 14.307

View more
  409 in total

1.  Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Authors:  J Joseph Melenhorst; Michael C Milone; Saba Ghassemi; Selene Nunez-Cruz; Roddy S O'Connor; Joseph A Fraietta; Prachi R Patel; John Scholler; David M Barrett; Stefan M Lundh; Megan M Davis; Felipe Bedoya; Changfeng Zhang; John Leferovich; Simon F Lacey; Bruce L Levine; Stephan A Grupp; Carl H June
Journal:  Cancer Immunol Res       Date:  2018-07-20       Impact factor: 11.151

2.  Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer.

Authors:  Andrew H Ko; Alexander C Jordan; Evan Tooker; Simon F Lacey; Renee B Chang; Yan Li; Alan P Venook; Margaret Tempero; Lloyd Damon; Lawrence Fong; Mark H O'Hara; Bruce L Levine; J Joseph Melenhorst; Gabriela Plesa; Carl H June; Gregory L Beatty
Journal:  Mol Ther       Date:  2020-07-21       Impact factor: 11.454

Review 3.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 4.  Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.

Authors:  Michael C Jensen; Stanley R Riddell
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 5.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 6.  Rapamycin-resistant effector T-cell therapy.

Authors:  Daniel H Fowler
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 7.  Hematopoietic stem cells for cancer immunotherapy.

Authors:  Eric Gschweng; Satiro De Oliveira; Donald B Kohn
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 9.  Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy.

Authors:  Joseph G Crompton; Madhusudhanan Sukumar; Nicholas P Restifo
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

10.  Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells.

Authors:  Francesca Giannoni; Cinnamon L Hardee; Jennifer Wherley; Eric Gschweng; Shantha Senadheera; Michael L Kaufman; Rebecca Chan; Ingrid Bahner; Vivian Gersuk; Xiaoyan Wang; David Gjertson; David Baltimore; Owen N Witte; James S Economou; Antoni Ribas; Donald B Kohn
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.